Literature DB >> 20042048

Pigs transgenic for human thrombomodulin have elevated production of activated protein C.

Björn Petersen1, Wolf Ramackers, Andreas Tiede, Andrea Lucas-Hahn, Doris Herrmann, Brigitte Barg-Kues, Wolfgang Schuettler, Lars Friedrich, Reinhard Schwinzer, Michael Winkler, Heiner Niemann.   

Abstract

BACKGROUND: The inability of porcine thrombomodulin (TM) to activate human anticoagulant protein C after pig-to-human xenotransplantation may lead to an aberrant activation of coagulation with microthrombosis and ultimately failure of the transplanted organ. Here, we describe the production of triple-transgenic pigs expressing hCD59/DAF and human thrombomodulin (hTM) and tested hTM-transgenic fibroblasts obtained from these pigs for their ability to activate human protein C in a new in vitro assay.
METHODS: Fibroblast cell cultures were established from a hCD59/DAF transgenic pig and transfected with a vector coding for hTM under transcriptional control of the CMV promoter. Transfected cells were analyzed for integration and expression of the hTM vector by PCR and RT-PCR. One cell clone was used as donor for somatic cell nuclear transfer to produce triple transgenic (CD59/DAF/hTM) pigs. Pigs were characterized in detail with regard to hTM integration and expression by PCR, RT-PCR, Northern blot, Western blot, immunostaining, and FACS analysis. Fibroblasts from hTM-transgenic pigs were analyzed in a new in vitro hTM coactivity assay to assess the production of activated protein C (aPC) and results were compared to those from wild-type controls.
RESULTS: In total, 1040 cloned transgenic embryos were transferred to eight recipients. Five recipients remained pregnant and delivered 22 piglets. Expression of hTM was detected in all xenorelavant organs including heart, liver, kidney, lung, and pancreas. The lowest levels of expression were found in lung and liver while all animals showed a strong, but frequently patchy expression pattern of hTM in heart, kidney, and pancreas. The hTM cofactor activity (ranging on a scale from 5-18 U/10(5) cells/2h) was significantly higher in fibroblasts of hTM-transgenic clones compared to wild-type porcine fibroblasts (1.7 U/10(5) cells/2h).
CONCLUSIONS: For the first time, healthy hTM-transgenic pigs could be successfully generated by somatic cell nuclear transfer. hTM can be expressed in porcine organs without perturbation of the porcine coagulation system. hTM-transgenic porcine fibroblasts showed elevated aPC production in an in vitro hTM coactivity assay. These findings warrant further work on the control of the xenogenic activation of coagulation by transgenic approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042048     DOI: 10.1111/j.1399-3089.2009.00537.x

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  35 in total

1.  The case for xenotransplantation.

Authors:  David K C Cooper
Journal:  Clin Transplant       Date:  2015-02-28       Impact factor: 2.863

Review 2.  Current status of pig heart xenotransplantation.

Authors:  Muhammad M Mohiuddin; Bruno Reichart; Guerard W Byrne; Christopher G A McGregor
Journal:  Int J Surg       Date:  2015-08-28       Impact factor: 6.071

Review 3.  Xenotransplantation--the future of corneal transplantation?

Authors:  Hidetaka Hara; David K C Cooper
Journal:  Cornea       Date:  2011-04       Impact factor: 2.651

Review 4.  Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future.

Authors:  Zhengzhao Liu; Wenbao Hu; Tian He; Yifan Dai; Hidetaka Hara; Rita Bottino; David K C Cooper; Zhiming Cai; Lisha Mou
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

5.  Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Jay Bhama; Hidetaka Hara; Mohamed Ezzelarab; Edwin Klein; Robert Wagner; Cassandra Long; Jnanesh Thacker; Jiang Li; Hao Zhou; Maolin Jiang; Santosh Nagaraju; Huidong Zhou; Massimiliano Veroux; Pietro Bajona; Martin Wijkstrom; Yi Wang; Carol Phelps; Nikolai Klymiuk; Eckhard Wolf; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

6.  Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases.

Authors:  Janet Hauschild; Bjoern Petersen; Yolanda Santiago; Anna-Lisa Queisser; Joseph W Carnwath; Andrea Lucas-Hahn; Lei Zhang; Xiangdong Meng; Philip D Gregory; Reinhard Schwinzer; Gregory J Cost; Heiner Niemann
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

Review 7.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 8.  Lung xenotransplantation: recent progress and current status.

Authors:  Donald G Harris; Kevin J Quinn; Siamak Dahi; Lars Burdorf; Agnes M Azimzadeh; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-07-05       Impact factor: 3.907

Review 9.  Overcoming Coagulation Dysregulation in Pig Solid Organ Transplantation in Nonhuman Primates: Recent Progress.

Authors:  Liaoran Wang; David K C Cooper; Lars Burdorf; Yi Wang; Hayato Iwase
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

10.  Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.

Authors:  Jan-Michael Abicht; Ioannis Kourtzelis; Bruno Reichart; Sophia Koutsogiannaki; Alexandra Primikyri; John D Lambris; Triantafyllos Chavakis; Lesca Holdt; Alexander Kind; Sonja Guethoff; Tanja Mayr
Journal:  Xenotransplantation       Date:  2016-09-27       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.